Annual Relapse Rate Disability Progression
1. BG12 53% 38%
2. Cladribine 58% 33%
3. Fingolimod 54% 30%
4. Laquinimod 23% 36%
5. Teriflunomide 32% 30%
Please remember that all agents are associated with particular side-effects and other attributes; hence the decision on which one is more appropriate for a particular person will require some careful thought. Individualised Medicine!
CoI: I have conflicts of interests in relation to all of these compounds. Barts and The London is involved in the clinical development of all of these compounds and I personally have received compensation for acting as an advisor to Biogen-Idec (BG12), Merck-Serono (Cladribine), Novartis (Fingolimod), Teva (Laquinimod) and Sanofi-Aventis (Teriflunomide).